Antiplatelet therapy: Anti-ischemic benefits versus bleeding risk

Journal of Interventional Cardiology

Volumn 21, Issue SUPPL. 1, 2008, Pages

  Gibson, C Michael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PLACEBO; TENECTEPLASE; TICLOPIDINE; WARFARIN;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; CARDIOTOXICITY; CARDIOVASCULAR EVENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MORBIDITY; MORTALITY; NON ST ELEVATION MYOCARDIAL INFARCTION; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; THERAPY DELAY; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; ISCHEMIA; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 56849091335     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2008.00407.x     Document Type: Conference Paper

References (26)

1. Rosamond W, Flegal K, Friday G, et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 115 : e69 e171. Available at : http://circ.ahajournals.org/cgi/content/ full/115/5/e69/DC1. Accessed December 12, 2007.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007 50 : e1 e57. Available at : http://content.onlinejacc.org. Accessed December 12, 2007.
3. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999 281 : 707 713.
4. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000 284 : 835 842.
5. Sabatine MS, Hamdalla HN, Mehta SR, et al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J 2008 155 : 910 917.
6. Kastrati A, Mehilli J, Schühlen H, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004 350 : 232 238.
7. Kastrati A, Mehilli J, Neumann FJ, et al. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006 295 : 1531 1538.
8. Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008 29 : 1504 1509.
9. Stone GW, McLaurin BT, Cox DA, et al., ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 355 : 2203 2216.
10. Moliterno DJ. Advances in antiplatelet/antithrombotic therapy for ACS and PCI. J Interven Cardiol (in press).
11. Gibson CM, Buros JL, Scirica B, et al. Presented at American College of Cardiology 56th Annual Scientific Session, New Orleans, LA, 2007.
12. Stone GW, Bertrand ME, Moses JW, et al., ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing trial. JAMA 2007 297 : 591 602.
13. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001 358 : 527 533.
14. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006 48 : 281 286.
15. Angiollo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004 25 : 1903 1910.
16. Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: Value of a high-loading-dose regimen. Catheter Cardiovasc Interv 2002 55 : 436 441.
17. Gruberg L. Clopidogrel preload prior to percutaneous coronary intervention: The ARMYDA-4 and ARMYDA-5 trials. Medscape Cardiol. Available at : http://www.medscape.com/viewarticle/572706. Accessed July 28, 2008.
18. Delaney JA, Opatrny L, Brophy JM, et al. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007 177 : 347 351.
19. Sonveaux P, Lobysheva II, Feron O, et al. Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: Role in oxygen delivery. Physiology 2007 22 : 97 112.
20. Reynolds JD, Ahearn GS, Angelo M, et al. S-nitrosohemoglobin deficiency: A mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci USA 2007 104 : 17058 17062.
21. Kirtane AJ, Piazza G, Murphy SA, et al., TIMI Study Group. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: Observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006 47 : 2374 2379.
22. Gibson CM, Morrow DA, Murphy SA, et al., TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006 47 : 2364 2373.
23. Sica D. The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002 14 (Suppl 2 30B 37B.
24. Marmur JD, Mitre CA, Barnathan E, et al. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am Heart J 2006 152 : 876 881.
25. Mehta RH, Alexander JH, Van de Wert F, et al. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. JAMA 2005 293 : 1746 1750.
26. Alexander KP, Chen AY, Roe MT, et al., CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005 294 : 3108 3116.